Hussam Suradi, MD
Interventional Cardiology · Chicago, ILNPI 1992962450
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $58,860 of the $96,889 with a category attached, or 60.8%. 22 manufacturers reported payments, led by Medical Device Business Services, Inc. at 33.0% of the total. Among interventional cardiology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $324.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$32K
- W. L. Gore & Associates, Inc.$27K
- Edwards Lifesciences$15K
- Medtronic$13K
- Boston Scientific$3K
- Abbott$2K
- plus $5K from 16 others
Across 94 payments — averaging $3805.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$196K
- Abbott$111K
- W. L. Gore & Associates, Inc.$51K
What the payments were for
- Consulting fees$58,86061%
- Speaking & faculty fees$11,39612%
- Travel & lodging$15,74016%
- Food & beverage$10,87011%
- Entertainment$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 22 | $31,985 |
| W. L. Gore & Associates, Inc. | 32 | $26,727 |
| Edwards Lifesciences | 58 | $14,508 |
| Medtronic(2 entities) | 51 | $12,684 |
| Boston Scientific | 46 | $3,486 |
| Abbott | 43 | $2,180 |
| Abiomed | 18 | $2,005 |
| Biosense Webster, Inc. | 1 | $900 |
| Asahi Intecc USA, Inc. | 1 | $833 |
| Endologix LLC | 4 | $540 |
| Cardiovascular Systems Inc. | 5 | $293 |
| Teleflex LLC | 1 | $163 |
| Cardiac Dimensions, Inc. | 1 | $130 |
| Livanova USA, Inc. | 4 | $126 |
| Philips North America LLC | 3 | $113 |
| Opsens Inc. | 2 | $62 |
| Cardiva Medical, Inc. | 2 | $60 |
| AbbVie | 1 | $29 |
| EKOS Corporation | 1 | $18 |
| Terumo Medical Corporation | 1 | $16 |
| Cook Medical LLC | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GORE CARDIOFORM Septal Occluder$24,884
- Carto 3 System$17,832
- Carto 3$14,850
- Edwards SAPIEN 3 Transcatheter Heart Valve$10,831
- APOLLOTM$3,811
- Impella$1,362
- EXCLUDER AAA Endoprosthesis$1,333
- EVOQUE$1,250
- AVVIGO Guidance System$1,132
- ASAHI PTCA Guide Wire$833
- CROSSBOSS$642
- GENERAL VASCULAR ACCESS$606
- Mitra Clip system$450
- Ovation$414
- MitraClip$334
- MitraClip System$312
- COREVALVE EVOLUT R$273
- Coronary Orbital Atherectomy System$245
- 3F$182
- THE EDWARDS SAPIEN 3 VALVE WITH ALTERRA ADAPTIVE PRESTENT SYSTEM$165
How this compares
$96,889 in reported general payments places this provider in the 90th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 77 | $102,060 |
| EntrestoSacubitril/Valsartan | 44 | $50,692 |
| FarxigaDapagliflozin Propanediol | 41 | $33,871 |
| JardianceEmpagliflozin | 26 | $30,928 |
| XareltoRivaroxaban | 21 | $30,213 |
| Repatha SureclickEvolocumab | 15 | $17,452 |
| BrilintaTicagrelor | 11 | $9,533 |
| Metoprolol Succinate | 134 | $1,473 |
| Atorvastatin Calcium | 161 | $1,466 |
| Amiodarone Hcl | 18 | $1,063 |
| Enoxaparin Sodium | 11 | $989 |
| Ezetimibe | 25 | $871 |
| ClopidogrelClopidogrel Bisulfate | 75 | $849 |
| Bumetanide | 26 | $804 |
| Furosemide | 124 | $556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $15 | $30,21321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Chicago
- Atman ShahChicago$788K
- David StewartChicago$169K
- Anita AsgarChicago$85K
- Daniel SchimmelChicago$79K
- Ranya SweisChicago$62K
- Charles DavidsonChicago$62K
- Fareed Moses ColladoChicago$42K
- James FlahertyChicago$38K
- Ashvarya ManglaChicago$36K
- Marysa LeyaChicago$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.